Abstract
Macrophage-derived IGF1 drives acquired resistance to CSF1R blockade in mouse models of GBM.
Major finding: Macrophage-derived IGF1 drives acquired resistance to CSF1R blockade in mouse models of GBM.
Mechanism: IL4 induces secretion of IGF1 from TAMs, activating IGF1R and PI3K signaling in tumor cells.
Impact: Combined inhibition of CSF1R and IGF1R or PI3K may improve overall survival in patients with GBM.
Therapeutic targeting of the tumor microenvironment is a promising strategy for treating glioblastoma multiforme (GBM), which is characterized by abundant tumor-associated macrophages (TAM). Colony-stimulating factor-1 receptor (CSF1R) inhibitors targeting these TAMs have shown activity in mouse models of high-grade GBM and are under evaluation in clinical trials. However, the long-term effects of CSF1R blockade in GBM are unknown, prompting Quail and colleagues to investigate whether CSF1R inhibition leads to acquired resistance. In a mouse model of GBM, treatment with a small-molecule inhibitor of CSF1R, BLZ945, resulted in substantial tumor regression in all animals, followed by a dormancy phase and the acquisition of drug resistance in 56% of mice. Recurrent tumors exhibited increased PI3K signaling, and combined treatment with the PI3K inhibitor BKM120 extended median survival, indicating that PI3K signaling underlies CSF1R inhibitor resistance. This resistance was mediated by the tumor microenvironment, as intracranially transplanted GBM cells isolated from recurrent tumors responded to CSF1R inhibition with BLZ945 in naïve hosts. Recurrent tumors developed adjacent to glial scarring and harbored protumorigenic TAMs that exhibited upregulation of a wound-associated gene program driven by IL4. In particular, expression of the IL4 target gene Igf1 in rebound TAMs was mediated by the NFAT and STAT6 transcription factors and stimulated the proliferation of recurrent tumor cells via activation of tumor cell IGF1R and downstream PI3K signaling. Consequently, treatment with an IGF1R inhibitor, OSI906, in combination with CSF1R blockade extended survival in genetic models of GBM and patient-derived orthotopic xenografts. Together, these results provide a mechanism by which the tumor microenvironment can promote resistance to CSF1R blockade, and suggest that combined inhibition of IGF1R, PI3K, or NFAT may improve survival in patients with GBM.
Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/content/early/by/section.